[Federal Register Volume 84, Number 169 (Friday, August 30, 2019)]
[Notices]
[Page 45769]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18730]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-D-2991]


Pediatric Rare Diseases--A Collaborative Approach for Drug 
Development Using Gaucher Disease as a Model; Draft Guidance for 
Industry; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Pediatric Rare Diseases--A Collaborative Approach for Drug 
Development Using Gaucher Disease as a Model; Draft Guidance for 
Industry; Availability'' that appeared in the Federal Register of 
December 7, 2017. The document announced the availability of a draft 
guidance focusing on drug development for pediatric patients with 
Gaucher disease. The document was published with the incorrect docket 
number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food 
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, 
Silver Spring, MD 20993-0002, 301-796-9115.

SUPPLEMENTARY INFORMATION: In the Federal Register of Thursday, 
December 7, 2017 (82 FR 57759), in FR Doc. 2017-26357, the following 
correction is made:
    On page 57759, in the first column, in the document heading and in 
the third column under Instructions, the docket number ``FDA-2017-N-
6476'' is corrected to read ``FDA-2017-D-2991''.

    Dated: August 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-18730 Filed 8-29-19; 8:45 am]
BILLING CODE 4164-01-P


